Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 182 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China MOST POPULAR Opportunity and mentorship: Our new PhD programme aiming to open-up academia... July 22, 2022 Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... June 19, 2019 Neoadjuvant Toripalimab Combined with Axitinib Demonstrates a Promising Pathologic Response Rate... December 5, 2023 Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of... March 26, 2026 Load more HOT NEWS Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... Understanding Genomic Correlates of Response and Acquired Resistance to FGFR Inhibitors Cancer in My Community: How People With Cancer Access Care in... PET Positivity After Two Cycles of ABVD Is Associated with a...
